   body {font-family: 'Open Sans', sans-serif;}

table { width: 100%; } table caption { text-align: left; } table thead th { text-align: left; } table td { text-align: left; padding: 6px; width: 100%; border-bottom-style: ridge; border-bottom-width: thin; border-bottom-color: Gray; } table th { text-align: left; padding: 6px; white-space: nowrap; border-bottom-style: ridge; border-bottom-width: thin; border-bottom-color: Gray; }

# Adenosine (Adenocard) Pharmacology and Notes  

  

**Indications:**  

Exclusively to convert supraventricular tachycardia to convert to sinus rhythm.

Mechanism: Complex conduction slowing AV Node

* * *

**Class**:  

Antiarrhythmic, endogenous nucleoside  

* * *

**Half-Life**:  

<10 seconds

* * *

**Actions:**  

Slows AV conduction

* * *

**Metabolism**:  

Rapidly taken up by erythrocyes and vascular endothelial cells, becomes part of body pool of nucleosides.  
**Elimination:**

* * *

**Dosing**  

Frequency: repeat doses can be given as early as 2 minutes after  
initial dose

* * *

**Administration**:  

should be given in most central venous access site as  
rapidly as possible. Central venous access is preferred but not essential.

* * *

**Precautions**:

May produce a short-lasting first, second or third degree AV block-especially at the time of cardioversion. Use with caution in patients with asthma.

If unsuccessful after 3 doses, or patient becomes unstable, synchronized cardioversion should be performed.

* * *

**Adverse Effects:  
**Facial flushing  
headache  
transient dyspnea  
shortness of breath  
dizziness  
chest pain  
bradycardia or sinus pause  
nausea